Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder

Table 2 Patient Demographics

Variable		Black Descent	White Descent	P-values
		(N = 372)	(N = 602)
Gender	Male	264 (71.0%)	399 (66.3%)	0.132
	Female	108 (29%)	203 (33.7%)
Age (yrs)	Mean	39.96	39.79	0.514
	SD	9.48	10.91
	Median	40.49	39.85
Weight (kg)	Mean	86.62	84.01	0.257
	SD	21.93	20.73
	Median	82.43	81.12
BMI (kg/m2)		N = 362	N = 596	0.587
	Mean	29.06	28.47
	SD	6.95	6.51
	Median	28.15	27.33
Geographic Region	USA	324 (87%)	416 (69.1%)	<0.001
	Europe	4 (1.1%)	107 (17.8%
	South America	37 (10%)	76 (12.6%)
	Other	7 (1.9%)	3 (0.5%)
PANSS Total	Mean	88.15	89.27	0.528
	SD	15.45	17.66
	Median	87.0	88
PANSS Positive	Mean	21.31	21.08
	SD	5.05	5.98
	Median	21.5	21
Diagnosis	Schizophrenia	322 (86.6%)	459 (76.3%)	<0.001
	Schizoaffective	50 (13.4%)	139 (23.1%)	<0.001
	Schizophreniform	0 (0%)	4 (0.7%)	0.298
CGI Score	Mean	N = 329	N = 505	0.002
	SD	4.42	4.60
	Median	0.69	0.78
		4.00	4.00
# Previous Episodes		N = 184	N = 341	0.296
	Mean	8.53	7.07
	SD	7.53	8.98
	Median	6.0	4.0
Illness Duration		N = 368	N = 600	0.547
	Mean	16.83	15.92
	SD	10.38	10.43
	Median	15.45	15.17

Abbreviations: N = All randomized patients with at least one post-baseline visit; SD = Standard Deviation; BMI = Body max index; PANSS = Positive and negative syndromes scale; CGI = Clinical global impression

ISSN: 1471-244X